Showing 7071-7080 of 19322 results for "".
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication
https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12678/Hear top strategies for monitoring disease progression and deciding courses of treatment for those with autosomal dominant polycystic kidney disease.Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerBridging the Gap in AYA Cure Rates
https://reachmd.com/programs/medical-industry-feature/bridging-the-gap-in-aya-cure-rates/35630/Explore the latest data on asparaginase-based therapies for adolescents and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma. For US HCPs Only.Multidisciplinary Team Collaboration in the New Era of Hemophilia Treatment
https://reachmd.com/programs/cme/multidisciplinary-team-collaboration-in-the-new-era-of-hemophilia-treatment/35554/Don’t miss this opportunity to learn the latest in new and emerging hemophilia therapies and optimize your patient care strategies.MOA: CDH6-Targeted Antibody-Drug Conjugates
https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerPulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
https://reachmd.com/programs/cme/pulmonary-hypertension-getting-the-right-diagnosis-and-knowing-when-to-refer/36094/Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to ReferAn Overview of Current and Emerging Treatment Options for Hemophilia A & B
https://reachmd.com/programs/cme/an-overview-of-current-and-emerging-treatment-options-for-hemophilia-a-b/35546/Don’t miss this opportunity to learn the latest in new and emerging hemophilia therapies and optimize your patient care strategies.TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/Are you as excited as we are to see how TROP2-targeted antibody-drug conjugates can help our patients?ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/Dr. Reshma Mahtani presents patient case challenges highlighting the use of antibody-drug conjugates in HER2-expressing metastatic breast cancer.From Risk to Results: Cases in ASCVD Prevention and Treatment
https://reachmd.com/programs/cme/from-risk-to-results-cases-in-ascvd-prevention-and-treatment/29823/Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthc